Atreca is a biopharmaceutical company developing novel therapeutics based on a deep understanding of the human immune response.

We focus in a unique way on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies, including those in our lead programs in oncology.

The proprietary Atreca Discovery Platform has been validated repeatedly via partnerships with major pharmaceutical companies, non-profit foundations, academic institutions, and governmental entities. Our experienced leadership is supported by recognized technical advisors and leading investors dedicated to building a company with a worldwide and lasting impact on human health.